Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Gross Margin (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Gross Margin for 9 consecutive years, with 90.49% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 473.0% to 90.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 87.49% through Dec 2025, up 308.0% year-over-year, with the annual reading at 87.49% for FY2025, 308.0% up from the prior year.
  • Gross Margin for Q4 2025 was 90.49% at BeOne Medicines, up from 86.09% in the prior quarter.
  • The five-year high for Gross Margin was 94.61% in Q1 2021, with the low at 75.82% in Q2 2021.
  • Average Gross Margin over 5 years is 83.34%, with a median of 83.35% recorded in 2023.
  • The sharpest move saw Gross Margin soared 2178bps in 2021, then tumbled -1588bps in 2022.
  • Over 5 years, Gross Margin stood at 77.31% in 2021, then grew by 4bps to 80.66% in 2022, then rose by 3bps to 83.32% in 2023, then rose by 3bps to 85.76% in 2024, then rose by 6bps to 90.49% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 90.49%, 86.09%, and 87.49% for Q4 2025, Q3 2025, and Q2 2025 respectively.